Do GLP-1 agonists achieve meaningful weight loss in patients with RMDs? RISE registry Retrospective N=60,206 Tirzepatide: lost 8% Semaglutide: list 6% At 12 months PsA had the highest usage OP0112 #EULAR2026 @RheumNow https://t.co/P3CTgiwqCr